

Technical Data Sheet

PE conjugated Human OX40 (C-Fc-Avi)

Catalog Number: 818201, 818202

Size: 25 ug, 100 ug

Target Name: TNFRSF4, OX40, CD134, OX40L receptor

Regulatory Status: RUO

Product Details

Application: FC

Format: Liquid, PE

Expression Host: CHO

Species: Human

Sources: Recombinant Human OX40 (Lue29-Ala216) with C-terminus Fc-Avi-tag is expressed in CHO cell and conjugated to PE.

Accession Number: P43489

Molecular Weight: The protein has a predicted molecular weight of 48.5 kDa. Under DTT-reducing conditions, it migrates at approximately 65 kDa on SDS-PAGE prior to conjugation.

Affinity Tag: C-Fc-Avi

Formulation: 1xPBS buffer, pH7.4, 0.09% NaN₃ with a carrier protein

Endotoxin level: Not tested

Protein Concentration: 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration.

Storage and Handling: Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months.

Background Information

OX40 (CD134) and its ligand OX40L (CD252), both part of the TNF receptor superfamily, play a key role in immune regulation. Their interaction is essential for T-cell expansion, survival, and cytokine production, influencing T cells, antigen-presenting cells, NK cells, and NKT cells. OX40-OX40L signaling helps break immune tolerance in malignancies, promoting antitumor immunity, and is also involved in the development of inflammatory and autoimmune diseases. Due to these regulatory effects, the OX40-OX40L pathway is a promising target for therapeutic interventions in both cancer and infectious diseases, with OX40 stimulation showing potential for therapeutic immunization strategies.